The commercialization/R&D of innovative drugs is constantly achieving new breakthroughs, and it is recommended to pay attention to these companies

【Pharmaceutical Network Industry News】 Biomedical innovation is related to people's health, and the development of pharmaceutical industry is the fundamental embodiment and guarantee
of the people's pursuit of a better life.
The scale of clinical medical needs to be met in China is huge
.
Nowadays, under the trend of increasing market demand and market scale, many biomedical companies have entered the market for innovative drugs
.
The industry said that in the future, innovative drugs will continue to be the key layout objects in the industry, and commercialization/research and development will continue to achieve new progress, and it is recommended to pay attention to Kangfang Biologics, Rongchang Biologics, BeiGene, etc
.
Kangfang Biologics Kangfang Biologics is an innovative antibody new drug research and development company, focusing on antibody and protein drug development of biopharmaceutical companies, committed to the discovery and development of innovative antibody new drugs
with independent intellectual property rights.
Thanks to the continuous efficiency of the layout and development of new drugs, it has received high attention in the capital market, and successfully completed the placement of 24 million shares in July 2022, raising HK$580 million, providing strong support
for subsequent product development and commercialization.
Data show that Kangfang Bio achieved a total revenue of 163 million yuan in the first half of the year, an increase of 26.
8% year-on-year; R&D investment was RMB595 million, an increase of RMB31.
9 million
over the same period last year.
It is reported that in June this year, Kangfang Bio's PD-1/CTLA-4 double antibody new drug (cardonizumab injection, trade name: Kaitani) was successfully approved for listing, which is a tumor double immune checkpoint double antibody
approved for marketing.
According to the feedback of the terminal market, the clinical demand for the drug is strong, and the company also disclosed the information
of receiving nearly 100 million yuan in advance receipts in early July.
In addition, the company's rich self-developed pipelines have also quickly entered the harvest period, it is reported that the company currently has 5 products in stage III and later, 13 pipelines in the critical / III phase clinical stage, including the field of cancer cartonnil treatment of first-line cervical cancer, first-line gastric cancer, hepatocellular carcinoma, etc
.
Rongchang Bio Rongchang Bio has formed three major technology platforms with good synergy that constitute the company's core competitiveness
.
Based on the company's antibody and fusion protein platforms (RC48, RC18, RC28), ADC (RC48), and dual antibody (RC138, RC148, RC158), the company has developed more than 20 biologic drug candidates, including more than 10 in commercial, clinical research or IND preparation stages, covering more than 20 indications
in the three major disease areas of autoimmunity, oncology and ophthalmology 。 It is reported that Rongchang Biological Innovation Pharmacep, which was conditionally approved for listing by the State Food and Drug Administration in March 2021, has entered the national medical insurance catalogue
in 2021.
On September 19, Rongchang Biologics announced that it has completed a phase III confirmatory study of tetazeptide in the treatment of patients with systemic lupus erythematosus, reaching the preset clinical endpoint
.
In addition, the company seized the historical opportunity of the era of multispecific drugs, and Videsetronab was the first to take the lead
.
The approval of the posterior treatment of vadiccisetumab for gastric cancer and urothelial cancer not only meets the domestic clinical needs, but also significantly better than similar therapies
in terms of clinical efficacy.
BeiGene As a representative company in the biomedical innovation industry, BeiGene has become a global biotechnology company
based on science and with the ability to operate the entire industry value chain after more than ten years of development.
It is reported that with solid R&D capabilities and dedicated scientific research investment, BeiGene has established a strong global R&D strength and competitive advantage
.
With its multi-faceted and integrated innovative drug research and development capabilities, it has developed a number of innovative drugs including zebutinib, tirelizumab, pamipal and so on, and has achieved fruitful research and development results
.
According to the company's semi-annual data, the company's zebukinib achieved global sales of $233.
1 million in the first half of the year, an increase of 261.
3% year-on-year; Domestic sales of tirellizumab in the first half of the year reached US$192.
5 million, an increase of 55.
6%
year-on-year.
It is understood that the company currently has 16 commercialized anti-tumor drugs, in addition, the company has also built a deep and differentiated research and development pipeline
.
As of June 30, 2022, BeiGene has approximately 40 clinical drug candidates or commercial-stage products
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.